Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails
- PMID: 37632280
- DOI: 10.1111/apt.17640
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails
Comment in
-
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.Aliment Pharmacol Ther. 2023 Sep;58(6):634-635. doi: 10.1111/apt.17656. Aliment Pharmacol Ther. 2023. PMID: 37632281 No abstract available.
Comment on
-
Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.Aliment Pharmacol Ther. 2023 Sep;58(5):492-502. doi: 10.1111/apt.17622. Epub 2023 Jun 29. Aliment Pharmacol Ther. 2023. PMID: 37382397 Review.
References
REFERENCES
-
- Al Khoury A, Balram B, Bessissow T, Afif W, Gonczi L, Abreu M, et al. Patient perspectives and expectations in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2022;67(6):1956-74.
-
- Dignass A, Rath S, Kleindienst T, Stallmach A. Review article: translating STRIDE II into clinical reality -opportunities and challenges. Aliment Pharmacol Ther. 2023;58:492-502.
-
- Burisch J, Safroneeva E, Laoun R, Ma C. Lack of benefit for early escalation to advanced therapies in ulcerative colitis: critical appraisal of current evidence. J Crohns Colitis. 2023;jjad106. https://doi.org/10.1093/ecco-jcc/jjad106
-
- Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2020;51(9):831-42.
-
- Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-89.
Publication types
MeSH terms
LinkOut - more resources
Medical